

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER


21-572

Administrative Documents



SUBMISSION OF PATENT INFORMATION PURSUANT TO 21 C.F.R. § 314.53

<u>Patent No.</u>	<u>Expiration Date</u>	<u>Type of Patent</u>	<u>Patent Owner</u>
5,912,226	June 15, 2016	Drug Product	Eli Lilly and Company
6,468,967	September 24, 2019	Method of Use	Cubist Pharmaceuticals, Inc.




DECLARATION OF TIMOTHY J. DOUROS, ESQ.

The undersigned declares that U.S. Patent No. 5,912,226 covers the formulation, composition, and/or method of use of daptomycin. Daptomycin is the subject of this application no. 21 572 for which approval is being sought.

A handwritten signature in black ink that reads "Timothy J. Douros". The signature is written in a cursive style and is positioned above a horizontal line.

Timothy J. Douros
Chief Intellectual Property Counsel
Cubist Pharmaceuticals, Inc.



DECLARATION OF TIMOTHY J. DOUROS, ESQ.

The undersigned declares that U.S. Patent No. 6,468,967 covers the formulation, composition, and/or method of use of daptomycin. Daptomycin is the subject of this application no. 21 572 for which approval is being sought.

A handwritten signature in black ink that reads "Timothy J. Duros". The signature is written in a cursive style and is positioned above a horizontal line.

Timothy J. Duros
Chief Intellectual Property Counsel
Cubist Pharmaceuticals, Inc.

Trade Name: Cubicin™ Generic Name: Daptomycin for injection

Applicant Name: Cubist Pharmaceuticals, Inc.

Division: HFD- 520

Approval Date: September 12, 2003

PART I: IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, but only for certain supplements. Complete Parts II and III of this Exclusivity Summary only if you answer "YES" to one or more of the following questions about the submission.

a) Is it an original NDA? YES / X / NO / ___ /

b) Is it an effectiveness supplement? YES / ___ / NO / X /

If yes, what type (SE1, SE2, etc.)? _____

c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "NO.")

YES / X / NO / ___ /

If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.